AL-38583 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses AL-38583 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses AL-38583 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated InflammationCompletedPhase 2Alcon ResearchNCT01001091Written as AL-38583 ophthalmic solutionHow we know
- A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry EyeCompletedPhase 2Alcon ResearchNCT00893139Written as AL-38583 ophthalmic solution 0.05%How we know
- To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen ChallengeWithdrawnPhase 2Alcon ResearchNCT00881673Written as AL38583 Ophthalmic SolutionHow we know